34 companies across digital health, biotech, and medical devices. We invest at the earliest signal of category-defining potential.
Remote cardiac monitoring for post-surgical patients. Real-time data from discharge through recovery.
Gene therapy platform targeting rare inherited metabolic disorders with a focus on pediatric populations.
AI-powered pathology reading for early cancer detection. Reducing time-to-diagnosis in community hospital settings.
Smart orthopedic implants with real-time load monitoring. Enabling evidence-based post-surgical rehab protocols.
Predictive sepsis detection for ICU environments. Clinically validated model with 6-hour early-warning lead time.
CRISPR-based neurodegenerative disease treatments. Lead program targeting Huntington's disease in Phase I trials.
Wearable photobiomodulation device for chronic wound healing. FDA-cleared for diabetic ulcer management.
Care coordination platform for complex chronic disease patients. Acquired and integrated into a national health system.
Liquid biopsy platform for early-stage colorectal cancer screening. 87% sensitivity in prospective clinical study.
Closed-loop neurostimulation for treatment-resistant depression. Breakthrough Device designation received in 2025.
mRNA vaccine platform for infectious disease prevention. NYSE-listed following successful Phase III data readout.
Minimally invasive biosensor capsule for GI tract monitoring. First-in-class device with novel wireless telemetry.
We're always looking for the next generation of healthcare founders.
Pitch to Us